Search

Tim M Townes

from Vestavia, AL
Age ~73
Get Report
Also known as:
Timothy M Townes
Phone and address:
4687 Bridgewater Rd, Birmingham, AL 35243
(205) 967-3566
Related to:
William OwensThomas Townes, 35Jeannette Townes, 72Rebecca Townes, 45Margaret A Owens, 33
Connected to:
Adia L Townes, 49Ameer Townes, 33Antwan J Townes, 36Carol A Townes, 71Dale Townes, 61Deelynn Townes, 45Donna M Townes, 64Erin N Townes, 33Ernest J Townes, 49Gabriel A Townes, 32

Tim Townes Phones & Addresses

  • 4687 Bridgewater Rd, Birmingham, AL 35243 (205) 967-3566
  • 4033 N Cahaba Dr, Birmingham, AL 35243
  • 4033 Cahaba St, Birmingham, AL 35243
  • Vestavia, AL
  • Pawleys Island, SC
  • 4370 Siwel Rd, Conway, SC 29526
  • 2213 Buttercup Ln, Conway, SC 29526
  • North Myrtle Beach, SC
  • 4687 Bridgewater Rd, Birmingham, AL 35243

Work

Company: Triad Position: Director patient access

Industries

Information Technology And Services

Resumes

Resumes

Tim Townes Photo 1

Director Patient Access

View page
Location:
Birmingham, AL
Industry:
Information Technology And Services
Work:
Triad
Director Patient Access

Business Records

Name / Title
Company / Classification
Phones & Addresses
Tim Townes
Information Technology Manager
Physicians Medical Center, LLC
Healthcare Facility Operator
Birmingham, AL 35234
1600 Carraway Blvd, Birmingham, AL 35234
(205) 502-6000
Tim Townes
Chief Information Officer, Director Information Technology
Affinity Hospital LLC
Hospital & Health Care · General Hospital · Management Services
800 Montclair Rd, Birmingham, AL 35213
PO Box 10065, Birmingham, AL 35202
(205) 592-5919
Tim Townes
Principal
Carraway Medical Center
General Hospital
1600 Carraway Blvd, Birmingham, AL 35234
Tim Townes
Dir Is, MIS Director
Carraway Methodist Health Syst
Health and Allied Services, Nec, Nsk · Business Service · Federal Credit Union · Specialty Hospital General Hospital · Business Services · Specialty Hospitals, Except Ps
PO Box 362045, Birmingham, AL 35236
1600 Carraway Blvd, Birmingham, AL 35234
1615 Carraway Blvd, Birmingham, AL 35234
(205) 250-0485, (205) 251-9393, (205) 502-6000, (205) 226-5280

Publications

Us Patents

Method For Identifying A -Eklf

View page
US Patent:
6475740, Nov 5, 2002
Filed:
Sep 18, 2001
Appl. No.:
09/955518
Inventors:
Tim M. Townes - Birmingham AL
David Donze - Silver Spring MD
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
The invention features -erythroid krÃppel-like factors ( -EKLFs), and methods of using nucleic acids encoding -EKLFs to increase -globin gene expression in a cell.

Synthesis Of Functional Human Hemoglobin And Other Proteins In Erythroid Tissues Of Transgenic Non-Human Mammals

View page
US Patent:
6613957, Sep 2, 2003
Filed:
Sep 1, 1999
Appl. No.:
09/388401
Inventors:
Tim M. Townes - Birmingham AL
Thomas M. Ryan - Birmingham AL
Richard D. Palmiter - Seattle WA
Ralph L. Brinster - Gladwyne PA
Richard R. Behringer - Philadelphia PA
Assignee:
The UAB Research Foundation - Birmingham AL
International Classification:
A01K 67027
US Classification:
800 14, 800 21, 800 22, 800 25, 800 4, 800 5
Abstract:
The present invention relates to the synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic non-human animals and erythroid cell lines. It is based on the discovery that two of the five hypersensitivity sites of the -globin locus are sufficient to result in high level expression of human - or -globin transgenes.

Xanthine Oxidase Inhibition As A Strategy To Alleviate Oxidative Impairment Of Vascular Function

View page
US Patent:
20030158213, Aug 21, 2003
Filed:
Nov 18, 2002
Appl. No.:
10/298739
Inventors:
Bruce Freeman - Birmingham AL, US
Margaret Tarpey - Birmingham AL, US
Tom Ryan - Birmingham AL, US
Tim Townes - Birmingham AL, US
Mutay Aslan - Antalya, TR
International Classification:
A61K031/519
US Classification:
514/262100
Abstract:
Disclosed is a method for alleviating the oxidative impairment of vascular function by inhibiting the activity of xanthine oxidase, or active forms thereof. Xanthine oxidase levels have been shown to be increased by a variety of conditions, including sickle cell disease. In the present disclosure, allopurinol is used to inhibit xanthine oxidase activity. As a result of the inhibition of xanthine oxidase, .NO levels in a subject can be maintained. In addition to sickle cell disease, allopurinol inhibition of xanthine oxidase may be used to treat other conditions, including, but not limited to, respiratory distress, kidney disease, liver disease, ischemia-reperfusion injury, organ transplant, sepsis, burns, viral infections and hemorrhagic shock.

Delta-Erythroid Kruppel-Like Factors And Methods Of Use

View page
US Patent:
20030224381, Dec 4, 2003
Filed:
Nov 5, 2002
Appl. No.:
10/289152
Inventors:
Tim Townes - Birmingham AL, US
David Donze - Silver Spring MD, US
International Classification:
C12Q001/68
C07H021/04
C07K014/475
C12P021/02
C12N005/08
C12N015/86
US Classification:
435/006000, 435/456000, 435/069100, 435/320100, 435/372000, 530/399000, 536/023500
Abstract:
The invention features -erythroid krüppel-like factors ( -EKLFs), and methods of using nucleic acids encoding -EKLFs to increase -globin gene expression in a cell.

Transgenic Animals That Produce Human Hemoglobin

View page
US Patent:
20040133934, Jul 8, 2004
Filed:
Sep 10, 2003
Appl. No.:
10/659675
Inventors:
Tim Townes - Birmingham AL, US
Thomas Ryan - Birmingham AL, US
Dominic Ciavatta - Birmingham AL, US
International Classification:
A01K067/027
US Classification:
800/018000
Abstract:
The invention features transgenic, non-human animals, such as mice, that produce human hemoglobin, for example, hemoglobin A, sickle hemoglobin, fetal hemoglobin, or hemoglobin Kansas Porto Alegre, but fail to produce hemoglobin endogenous to the animal. The invention also features methods for producing human hemoglobin in these animals, human hemoglobins produced by these methods, and methods of using these animals to identify therapeutic substances.

Polycistronic Vector For Human Induced Pluripotent Stem Cell Production

View page
US Patent:
20100150889, Jun 17, 2010
Filed:
Dec 17, 2009
Appl. No.:
12/640767
Inventors:
Tim Townes - Birmingham AL, US
Kevin M. Pawlik - Birmingham AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - Birmingham AL
International Classification:
A61K 45/00
C12N 5/10
C12N 15/74
A61P 35/00
US Classification:
424 9321, 435377, 435366, 435325, 4353201
Abstract:
Methods of producing induced pluripotent stem (iPS) cells are provided. For example, a method of producing an iPS cell from a differentiated cell, which includes transforming the differentiated cell with a first vector comprising a nucleic acid sequence comprising a nucleic acid sequence encoding an Oct4, a nucleic acid sequence encoding a Sox2, and a nucleic acid sequence encoding a Klf4. Each of the nucleic acid sequences are separated from each other by a first and second viral 2A sequence. The method described can further comprise culturing the transformed cell under conditions that allow for the production of an iPS cell and isolating the cultured iPS cell.

Polycistronic Vector For Human Induced Pluripotent Stem Cell Production

View page
US Patent:
20130017596, Jan 17, 2013
Filed:
May 25, 2012
Appl. No.:
13/480753
Inventors:
TIM TOWNES - BIRMINGHAM AL, US
KEVIN M. PAWLIK - BIRMINGHAM AL, US
Assignee:
THE UAB RESEARCH FOUNDATION - BIRMINGHAM AL
International Classification:
C12N 15/867
C12N 15/861
C12N 15/87
C12N 15/85
US Classification:
4353201
Abstract:
Methods of producing induced pluripotent stem (iPS) cells are provided. For example, a method of producing an iPS cell from a differentiated cell, which includes transforming the differentiated cell with a first vector comprising a nucleic acid sequence comprising a nucleic acid sequence encoding an Oct4, a nucleic acid sequence encoding a Sox2, and a nucleic acid sequence encoding a Klf4. Each of the nucleic acid sequences are separated from each other by a first and second viral 2A sequence. The method described can further comprise culturing the transformed cell under conditions that allow for the production of an iPS cell and isolating the cultured iPS cell.

Nucleic Acid Vectors Comprising Dnase I Hypersensitive Sites

View page
US Patent:
60227362, Feb 8, 2000
Filed:
Jun 6, 1995
Appl. No.:
8/471483
Inventors:
Tim M. Townes - Birmingham AL
Thomas M. Ryan - Birmingham AL
Richard D. Palmiter - Seattle WA
Ralph L. Brinster - Gladwyne PA
Richard R. Behringer - Philadelphia PA
Assignee:
The UAB Research Foundation - Birmingham AL
The Trustees of the University of Pennsylvania - Philadelphia PA
Board of Regents of the University of Washington - Seattle WA
International Classification:
C12N 1563
C12N 1509
C12N 1500
C12N 500
US Classification:
4353201
Abstract:
The present invention provides novel recombinant nucleic acid vectors which may be used to produce. alpha. -globin as well as other proteins of interest in quantity in the red blood cells of transgenic animals or cell cultures of erythroid lineage. The present invention also provides for the transgenic animals which contain these recombinant nucleic acid vectors. The vectors of the invention comprise at least one of the major DNase I hypersensitivity sites associated with the. beta. -globin locus together with a gene of interest. According to various embodiments of the invention, the vectors may be used to create transgenic animals or to transfect cells in culture. In a specific embodiment of the invention, a vector which comprises two DNase I hypersensitivity sites together with the human. alpha. -globin gene is used to create transgenic animals which produce human. alpha. -globin protein in erythroid tissues, including red blood cells.
Control profile
Tim M Townes from Vestavia, AL, age ~73 Get Report